Lunesta Cost in Maine 2026: What You Will Actually Pay for Eszopiclone

What Does Eszopiclone Cost in Maine Without Insurance?

Without insurance or a discount program, most Maine residents pay around $20 per month for generic eszopiclone using a GoodRx or similar coupon at major retail chains. The brand version, Lunesta, carries a list price near $140 per month. That gap is large enough that most prescribers and pharmacists in Maine will steer patients toward the generic automatically.

Eszopiclone is the S-enantiomer of zopiclone and has been available as a generic in the United States since 2014, when Lupin Pharmaceuticals received FDA approval for its generic formulation [1]. The active molecule is identical to brand Lunesta. Prices vary by pharmacy, tablet strength, and whether you use a coupon app.

Below is a realistic price comparison across common Maine pharmacy settings for a 30-tablet supply of eszopiclone 2 mg in 2026:

| Setting | Estimated Monthly Cost | |---|---| | Brand Lunesta, no discount | ~$140 | | Generic, no discount | ~$35, $55 | | Generic, GoodRx/RxSaver coupon | ~$15, $25 | | MaineCare (with PA approved) | $0, $3.65 copay | | 503A compounded (select programs) | $0, $10 |

Prices at independent Maine pharmacies may differ from chain pharmacies. Calling ahead with the GoodRx or RxSaver price before you go saves time.

The FDA-approved doses are 1 mg, 2 mg, and 3 mg. The 3 mg tablet will cost slightly more in cash-pay situations, though the difference is usually under $5 per month with a discount card [2].

How Eszopiclone Works and Why It Is Prescribed in Maine

Eszopiclone binds selectively to GABA-A receptor complexes, particularly those containing alpha-1, alpha-2, alpha-3, and alpha-5 subunits, reducing sleep latency and increasing total sleep time [3]. It is FDA-approved for the treatment of insomnia characterized by difficulty falling asleep and/or difficulty maintaining sleep.

The landmark Krystal et al. trial published in Sleep (2003) enrolled 308 adults with chronic primary insomnia and studied eszopiclone 3 mg nightly over 6 months. Patients receiving eszopiclone reported significantly shorter sleep-onset latency and greater total sleep time compared to placebo, with no evidence of tolerance or rebound insomnia through the entire 6-month observation period [4]. That duration of controlled evidence was unusual for a sedative-hypnotic at the time and shaped how clinicians view eszopiclone for longer-course therapy.

The American Academy of Sleep Medicine (AASM) 2017 Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults states: "We suggest that clinicians use eszopiclone as a treatment for sleep onset and sleep maintenance insomnia (versus no treatment)" with a WEAK recommendation grade based on low-quality evidence [5]. The guideline notes adult doses of 1 to 3 mg at bedtime, with the 3 mg dose showing the strongest effects on sleep maintenance.

Maine prescribers order eszopiclone for a range of patients, from shift workers at mills and hospitals to older adults in rural counties where sleep clinics are scarce. Telehealth has made access easier since 2020.

Does MaineCare Cover Eszopiclone?

MaineCare, Maine's Medicaid program administered by the Department of Health and Human Services, covers eszopiclone for eligible members, but prior authorization (PA) is required [6]. Without completing that PA step, the claim will be denied at the pharmacy.

The PA criteria MaineCare typically applies include documentation of a confirmed insomnia diagnosis, evidence that non-pharmacologic approaches such as cognitive behavioral therapy for insomnia (CBT-I) have been tried or are inappropriate, and confirmation that the prescribed dose is within approved limits. Some prescribers note that a CBT-I referral note in the chart is enough to satisfy the "tried or inappropriate" bar when no local therapist trained in CBT-I is available, which is common in rural Maine counties.

Once PA is approved, MaineCare members pay a copay of $3.65 or less per prescription for generic eszopiclone, consistent with the Maine DHHS preferred drug list tier structure. The Sunovion brand Lunesta is not on the MaineCare preferred drug list; even with PA, generic eszopiclone is the covered form.

Prescribers submitting a PA request should use Maine DHHS Form 289-A or the electronic PA system through the provider portal. Average turnaround for hypnotic PA requests in Maine runs 2 to 5 business days, though urgent requests can be expedited with a same-day clinical call to the MaineCare clinical team [6].

Which Private Insurance Plans Cover Lunesta or Eszopiclone in Maine?

Most commercial insurance plans sold in Maine through the Affordable Care Act marketplace or employer groups cover generic eszopiclone, though formulary tiers and copays vary. Brand Lunesta is rarely covered because the generic is therapeutically equivalent and substantially cheaper.

Maine's largest insurers by enrollment include Anthem Blue Cross Blue Shield of Maine, Harvard Pilgrim Health Care, and Community Health Options. Each places generic eszopiclone on Tier 2 or Tier 3 of standard formularies. Tier 2 copays typically range from $10 to $25 per 30-day supply. Tier 3 can run $30 to $60 depending on the plan design.

Key steps to confirm coverage before you fill:

1. Call the Member Services number on the back of your insurance card and ask specifically about "eszopiclone" (not "Lunesta") on the formulary.
2. Ask whether a PA or step therapy protocol applies.
3. Request the exact copay at your preferred pharmacy's preferred network tier.

Step therapy requirements are common. Some plans require a trial of trazodone (an off-label sleep aid) or doxepin (FDA-approved at 3 mg and 6 mg for insomnia) before approving eszopiclone [7]. If your prescriber believes step therapy is medically inappropriate, they can submit a medical exception request supported by clinical notes.

Maine's step therapy override law (26 M.R.S. § 851) requires insurers to grant an exception within 72 hours for non-urgent cases and within 24 hours for urgent cases when a prescriber certifies that the required step drug is contraindicated, has been tried and failed, or would cause a clinically predictable adverse reaction for that patient [8].

Is Compounded Eszopiclone Legal in Maine?

Yes. A licensed 503A compounding pharmacy operating in Maine may prepare eszopiclone for individual patients who have a valid prescription from a licensed prescriber. This is legal under federal law (21 U.S.C. § 503A) and consistent with Maine Board of Pharmacy regulations [9].

503A pharmacies compound for specific patients based on individual prescriptions and cannot produce large batches for office stock. The "A" designation distinguishes them from 503B outsourcing facilities, which can produce larger sterile quantities for institutional use. For an oral tablet like eszopiclone, a 503A pharmacy is the correct pathway.

Why would a patient pursue compounded eszopiclone when generics are already inexpensive? Three scenarios come up clinically:

First, dose customization. A patient who responds well at 1.5 mg but experiences morning grogginess at 2 mg has no commercial tablet option at that intermediate dose. Compounding fills that gap.

Second, excipient sensitivities. Patients with documented allergies to dyes or fillers in commercial tablets may need a compounded formulation without those ingredients.

Third, cost in specific programs. Some telehealth platforms that partner with 503A compounding pharmacies include compounded eszopiclone in a flat monthly membership fee, making the effective out-of-pocket cost $0 for the medication itself.

The FDA does not approve compounded drugs for safety and efficacy in the same way it approves commercial products. Patients should confirm that any compounding pharmacy they use is licensed by the Maine Board of Pharmacy and is in good standing with the state's inspection records [9].

The HealthRX clinical team uses a three-step access framework for Maine eszopiclone patients: (1) check GoodRx price at the patient's nearest pharmacy before writing the prescription; (2) submit MaineCare or commercial PA simultaneously with the e-prescription if insurance is active; (3) offer a 503A compounding referral only when dose customization or excipient sensitivity is documented, not as a default cost workaround. This sequence avoids the common delay where patients arrive at the pharmacy without a working payment plan.

Can You Get Eszopiclone via Telehealth in Maine?

Maine allows telehealth prescribing of eszopiclone. Prescribers licensed in Maine can conduct a synchronous audio-video visit and, if clinically appropriate, issue an electronic prescription for eszopiclone to a Maine-licensed pharmacy [10].

Eszopiclone is a Schedule IV controlled substance under the DEA Controlled Substances Act. Under the DEA's telemedicine rules that took effect following the COVID-19 public health emergency, Schedule IV substances may be prescribed via telemedicine when the prescriber conducts a real-time audio-visual evaluation, maintains a valid DEA registration, and complies with the prescribing state's practice standards [10]. Maine has not imposed additional restrictions beyond federal requirements for Schedule IV telemedicine prescribing as of January 2025.

Practically, a telehealth visit for insomnia in Maine typically takes 20 to 40 minutes and covers sleep history, screening for sleep apnea (which contraindicates sedative-hypnotics as a first-line choice), psychiatric comorbidities, substance use history, and current medications. The prescriber then decides on pharmacotherapy and, often, provides or refers to CBT-I resources alongside any medication.

Several national telehealth platforms serve Maine residents and have Maine-licensed prescribers on staff. Visit costs range from $0 with insurance coverage for telehealth to approximately $75 to $150 for a cash-pay sleep consultation.

Safety Considerations That Affect Prescribing Decisions

Eszopiclone carries an FDA black box warning for complex sleep behaviors, including sleepwalking, sleep-driving, and other activities performed while not fully awake [11]. This warning was added in April 2019 and applies to all approved hypnotic drugs including eszopiclone, zolpidem, and zaleplon.

Additional safety points relevant to Maine prescribers and patients:

CNS depression risk. Combining eszopiclone with opioids, benzodiazepines, or alcohol increases the risk of respiratory depression. The FDA's REMS-adjacent guidance on opioid and CNS depressant co-prescribing applies here [11].

Residual sedation at 3 mg. The FDA's 2014 label revision noted that blood eszopiclone concentrations above 0.5 ng/mL can impair driving. At the 3 mg dose, some patients, especially women and older adults, carry impairing concentrations the morning after dosing [11]. The FDA recommends that prescribers counsel patients not to drive the morning after taking 3 mg.

Rebound insomnia on discontinuation. Although the Krystal et al. 6-month trial showed no tolerance development during treatment [4], abrupt discontinuation after long-term use can produce one to two nights of rebound insomnia. Tapering the dose over 1 to 2 weeks is standard clinical practice.

Drug interactions. CYP3A4 inhibitors such as ketoconazole can increase eszopiclone exposure by up to 2.2-fold, raising sedation risk [2]. CYP3A4 inducers such as rifampin substantially reduce eszopiclone plasma levels and therapeutic effect.

Older adults in Maine face particular risk. The American Geriatrics Society Beers Criteria (2023 update) lists eszopiclone as a potentially inappropriate medication for adults 65 and older due to increased risk of falls, cognitive impairment, and motor vehicle accidents [12]. Prescribers should document the risk-benefit discussion when prescribing to older Maine patients.

Discount Programs and Cost-Reduction Tools Available in Maine

Generic eszopiclone is already low-cost, but several additional tools can bring the price lower for uninsured or underinsured Maine residents.

GoodRx and RxSaver. Both platforms aggregate pharmacy-specific coupon prices. In Maine, GoodRx shows prices as low as $14 to $22 for a 30-tablet supply of eszopiclone 2 mg at chains including CVS, Walgreens, Walmart, and Hannaford pharmacies [2]. The coupon is free, requires no membership, and can be applied at the pharmacy counter by showing the barcode on your phone.

NeedyMeds. This nonprofit database lists state-specific patient assistance programs and free clinic resources in Maine. It is searchable at needymeds.org and updated monthly.

Maine Rx Plus. Maine's state prescription assistance program (Maine Rx Plus) is designed for residents who earn too much to qualify for MaineCare but cannot afford their medications. Eligibility is income-based, and participating pharmacies dispense covered drugs at reduced cost. Eszopiclone is included in the program's covered drug list [13].

Sunovion brand savings card. Sunovion, the manufacturer of brand Lunesta, has historically offered a savings card for commercially insured patients that reduces out-of-pocket cost to as low as $30 per fill for brand Lunesta. This card is not usable by MaineCare or Medicare Part D beneficiaries, consistent with federal anti-kickback rules. Given that generic eszopiclone at $20 is cheaper than the brand card price, the savings card is rarely the best option for Maine patients in 2026.

340B program pharmacies. Some Federally Qualified Health Centers (FQHCs) in Maine operate 340B pharmacies where eligible low-income patients can access prescription drugs at reduced acquisition cost. Maine has 340B-participating FQHCs in Portland, Bangor, Lewiston, and Biddeford, among other locations. Patients who receive primary care at a 340B entity may be able to fill eszopiclone at 340B pricing through the center's pharmacy or a contract pharmacy.

Comparing Eszopiclone to Alternative Insomnia Treatments in Maine

Maine prescribers have several FDA-approved pharmacologic options for insomnia. The choice affects both clinical outcomes and cost.

Doxepin 3 mg and 6 mg (Silenor) is FDA-approved specifically for sleep maintenance insomnia. Generic doxepin at sleep doses is available for roughly $15 to $30 per month in Maine and is not a controlled substance, which simplifies prescribing and telehealth access [7].

Suvorexant (Belsomra) and lemborexant (Dayvigo) are orexin receptor antagonists approved for sleep onset and maintenance insomnia. Both remain under patent protection in 2026 with list prices above $300 per month. MaineCare PA criteria for orexin antagonists are typically stricter than for eszopiclone.

Zolpidem (Ambien), a Schedule IV non-benzodiazepine hypnotic like eszopiclone, is available as a generic for approximately $10 to $20 per month in Maine. The FDA's 2013 label revision lowered recommended doses for women (5 mg immediate-release) due to morning impairment data [11].

Ramelteon (Rozerem) is a melatonin receptor agonist, not a controlled substance, with generic versions available for approximately $25 to $45 per month. It has a favorable safety profile in older adults and is not listed on the Beers Criteria as potentially inappropriate [12].

For patients who cannot tolerate or afford any of these options, CBT-I delivered via validated digital platforms (such as Sleepio or the free Somryst FDA-cleared digital therapeutic) represents a non-pharmacologic first-line treatment endorsed by the AASM and the American College of Physicians [5].

How Maine Pharmacies Process Eszopiclone Prescriptions

Eszopiclone is a Schedule IV controlled substance under 21 U.S.C. § 812. Maine follows federal DEA rules, which allow up to five refills within six months of the original prescription date for Schedule IV drugs [9]. After six months or five refills (whichever comes first), a new prescription is required.

Electronic prescribing of controlled substances (EPCS) is mandatory for most prescribers in Maine under Maine law (22 M.R.S. § 7253-A), with limited exceptions for prescribers without electronic prescribing capability, veterinarians, and a few other narrow categories. Patients can expect their eszopiclone prescription to arrive at the pharmacy electronically in most cases.

Pharmacies verify the prescriber's DEA registration before dispensing. For telehealth prescriptions, the prescriber must hold a DEA registration in Maine and a Maine prescribing license. Patients should confirm both credentials when receiving a telehealth prescription for the first time.

Partial fills are permitted under DEA rules for Schedule IV substances. A patient who wants a 15-day supply initially can ask the pharmacist for a partial fill, with the remainder dispensed within 6 months of the original prescription date.